Acalabrutinib D4 (ACP196 D4) is the tetra-deuterated form of Acalabrutinib (ACP-196; trade name: Calquence), which is a selective and second-generation BTK inhibitor approved in 2017 by FDA to treat adults with mantle cell lymphoma.
纯度:≥98%
CAS:1420477-60-6 (unlabeled)